

FACTOR NOTES

BROUGHT TO YOU BY THE SOUTHWESTERN OHIO HEMOPHILIA FOUNDATION

EMBRACING THE VIRTUAL VENUE

The annual Women's Day Get Together Virtually Happened! While we didn't get to enjoy each other in person still we had a very informative and creative meeting in spite of our spatial differences. SWOHF has embraced the Virtual Venue, and we were thrilled that 24 women embraced it with us. We look to 2021 with a hopeful anticipation that we will reunite in person.

The afternoon began with a presentation from Sandra Valdovinos-Heredia LCSW, MSW and an advocate for the bleeding disorders community. Her workshop titled "The Things that aren't talked about", gave us permission to talk about...mental health. Such a timely topic during our lock down days, coupled with the stressors of living with or caring for a loved one with a bleeding disorder. She helped us to identify our anxieties and gave us some valuable coping tools and resources to assist with those helpless feelings. (See page 14 for a list of resources cited in this program).

The takeaways identified after the workshop were:

"Help is out there. We are all human and it is okay to ask for help!"

"Listening skills"

"I'm not as alone as I feel."

"There is help and support during these trying times so that we can combat anxieties and stress."

"Hope!"

"Take Care of Yourself."

"There are people to talk to."

The second half of our program consisted of an interactive Virtual art Project. Emily Murphy, Art Guide and Advocate of an Artistic Life walked us through creating a fantastical beaded wrapped tree. Emily's humor and extraordinary teaching skills brought out our creative proclivities. Opening ourselves up to something creative can be a wonderful escape, even for a moment. Wow some amazing results followed!!!

"The world always seems brighter when you've just made something that wasn't there before."

-Neil Gaiman

"Creativity takes Courage."


-Henri Matisse

"We don't make mistakes, just happy little accidents."

-Bob Ross

"Art is a line around your thoughts."

-Gustav Klimt



2020
ISSUE #4

- P. 1 Embracing the Virtual Venue
- P. 2 Happy Holidays & AmazonSmile
- P. 3 The Anxiety First Aid Kit
- P. 6-7 10th Annual Bleeding Disorder Awareness 5K
- P. 10 Thanks Virtual 5K Sponsors
- P. 14 Resources for Mental Health Information
- P. 15 HTC Corner

SOUTHWESTERN OHIO
HEMOPHILIA FOUNDATION
3131 South Dixie Drive, Suite 103
Moraine, OH 45439

P: (937) 298-8000
www.swohf.org


F: (937) 298-8080
joy@swohf.org



HAPPY
holidays

FROM ALL OF US AT THE
**SOUTHWESTERN OHIO
HEMOPHILIA FOUNDATION**

Help bring joy this season

Buy your gifts at AmazonSmile and Amazon donates


Did you know that when you shop for the holidays at smile.amazon.com/ch/31-1527065 AmazonSmile donates to the Southwestern Ohio Hemophilia Foundation? This is a simple way for you to support SWOHF while you shop, at no cost to you!

Tis the season to be generous!

Judy Doyle

Patient advocate

About Judy

Judy is a Novo Nordisk Hemophilia Community Liaison with 18 years of experience supporting those with bleeding disorders. She loves the passion of the hemophilia community to get things done and not let things stand in their way.

Connect with Judy

JDDL@novonordisk.com
(216) 217-4197



Hemophilia Community Liaison

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

©2020 Novo Nordisk Printed in the U.S.A. US20HRBD00247 October 2020



"If you're feeling unprecedented levels of stress and anxiety right now, please know that you aren't alone. In these extreme and uncertain times, it's natural to be in a constant state of mental and physical strain. Whether you're dealing with job loss, a sick loved one, or just feeling the weight of the world during your 2 a.m. doomscroll—you need quick tools you can use right now, whenever and wherever you are, to lower stress and soothe anxiety. This emergency kit has you covered."

Hope you enjoy!



SWOHF is grateful to FAMOHIO for providing this book to our women who attended the virtual program.

We have a limited number of books available and would love to mail one to you if you might find it helpful. Please email joy@swohf.org or call the SWOHF office at 937-298-8000 to request your copy.

and remember to SAVE THE DATE!



GO SEEK. GO EXPLORE.
GO AHEAD.

PEOPLE LIKE YOU. STORIES LIKE YOURS.
Explore more at HEMLIBRAjourney.com



Discover your sense of go. Discover HEMLIBRA.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba[®]) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- **Thrombotic microangiopathy (TMA)**, a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- **Blood clots (thrombotic events)**, which may form in blood vessels in your arm, leg, lung, or head

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including **Serious Side Effects**.

**HEMLIBRA.**
emicizumab-kxwh | 300 mg
injection for subcutaneous use | 78376

Medication Guide
HEMLIBRA® (hem-lee-bruh)
(emicizumab-kxwh)
injection, for subcutaneous use

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment.

HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:

- **Thrombotic microangiopathy (TMA).** This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
 - confusion
 - weakness
 - swelling of arms and legs
 - yellowing of skin and eyes
 - stomach (abdomen) or back pain
 - nausea or vomiting
 - feeling sick
 - decreased urination
- **Blood clots (thrombotic events).** Blood clots may form in blood vessels in your arm, leg, lung, or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
 - swelling in arms or legs
 - pain or redness in your arms or legs
 - shortness of breath
 - chest pain or tightness
 - fast heart rate
 - cough up blood
 - feel faint
 - headache
 - numbness in your face
 - eye pain or swelling
 - trouble seeing

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

See **"What are the possible side effects of HEMLIBRA?"** for more information about side effects.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.

HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use HEMLIBRA?

See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Use HEMLIBRA exactly as prescribed by your healthcare provider.
- **Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.**
- **You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.**
- HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.

- Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.
- You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.
- If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed dose as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. **Do not** give two doses on the same day to make up for a missed dose.
- HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

What are the possible side effects of HEMLIBRA?

- See **"What is the most important information I should know about HEMLIBRA?"**

The most common side effects of HEMLIBRA include:

- redness, tenderness, warmth, or itching at the site of injection
- headache
- joint pain

These are not all of the possible side effects of HEMLIBRA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store HEMLIBRA?

- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.
- Throw away (dispose of) any unused HEMLIBRA left in the vial.

Keep HEMLIBRA and all medicines out of the reach of children.

General information about the safe and effective use of HEMLIBRA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.

What are the ingredients in HEMLIBRA?

Active ingredient: emicizumab-kxwh

Inactive ingredients: L-arginine, L-histidine, poloxamer 188, and L-aspartic acid.

Manufactured by: Genentech, Inc., A Member of the Roche Group,
1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No. 1048

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

©2018 Genentech, Inc. All rights reserved.

For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Revised: 10/2018




HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The Genentech logo is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.
©2020 Genentech USA, Inc. All rights reserved. M-US-00007357(v1.0) 09/20


Genentech
A Member of the Roche Group

10TH ANNUAL BLEEDING DISORDER AWARENESS 5K

By Dena Shepard



It has certainly been said many times that 2020 is a year like no other we have ever experienced. It held true for the 10th Annual Bleeding Disorder Awareness 5K. For nine consecutive years we had run, jogged and walked at Miamisburg's Five Rivers Metro Park bike path in all types of weather with varying numbers of participants and support, but always with joy and commitment to support the bleeding disorders community.



As plans were underway for a 10th commemorative year it became apparent that we would need to cancel or flip to a virtual event. In an effort to keep the event we chose to go virtual. As the committee chair for the past several years I was hopeful for a successful event and successful is an understatement. The bleeding disorder community and our supporters showed up in an amazing way that surpassed our goals.

From generous supporters including Butler Heating and Air Conditioning, who was our major event sponsor, to our vendors:


Takeda, CSL Behring, Cascade, Biomarin, Novo Nordisk, Sanofi Genzyme, Bayer, Accredo, Medexus Pharma and Genetech to generous individual contributions we were able to raise over \$20,000.00; the largest amount in our 5K history.






We had over 130 participants at various locations, on various days and at various speeds that exhibited the true spirit of community that we have all come to know and love about the friends and family of the Southwest Ohio Hemophilia Foundation. The tremendous support shines a bright light during a time that our worlds have been dimmed by unstable times, tension and anxiousness. The dollars raised will go to support education, advocacy and special assistance to individuals and families.

Thank you does not seem like enough to express the gratitude that is felt. The Foundation is wishing you all more bright light moments that keep your hearts, minds and spirits hopeful and committed to supporting one another.

Looking forward to walking arm in arm in 2021.







EXPERIENCE MATTERS

BeneFix is FDA approved for once-weekly prophylaxis and on-demand use to fit your dosing needs—
from the only recombinant factor IX supporting individuals with hemophilia B for more than 20 years.*

Not actual patients.



More than 20 years* of experience—the first recombinant treatment for individuals with hemophilia B



Dosing options to meet your needs—for once-weekly prophylaxis and on-demand use



Designed with viral safety in mind. More than 150 quality control tests are done on each batch of BeneFix



The convenience of the BeneFix Rapid Reconstitution (R2) Kit with a range of vial sizes



**ASK YOUR DOCTOR WHICH BENEFIX[®]
DOSING OPTIONS MAY BE RIGHT FOR YOU**

What Is BeneFix?

BeneFix, Coagulation Factor IX (Recombinant), is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Your doctor might also give you BeneFix before surgical procedures.

BeneFix is **NOT** used to treat hemophilia A.

Important Safety Information

- BeneFix is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein.
- Call your health care provider right away if your bleeding is not controlled after using BeneFix.
- Allergic reactions may occur with BeneFix. Call your health care provider or get emergency treatment right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, your lips and gums turning blue, fast heartbeat, facial swelling, faintness, rash, or hives.
- Your body can make antibodies, called “inhibitors,” which may stop BeneFix from working properly.
- If you have risk factors for developing blood clots, such as a venous catheter through which BeneFix is given by continuous infusion, BeneFix may increase the risk of abnormal blood clots. The safety and efficacy of BeneFix administration by continuous infusion have not been established.
- Some common side effects of BeneFix are fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness, and rash.

Please see the Brief Summary for BeneFix on the next page.



BeneFix[®]

Coagulation Factor IX (Recombinant)

Room Temperature Storage

*BeneFix was approved February 11, 1997.

R_x only

Brief Summary

See package insert for full Prescribing Information. This product's label may have been updated. For further product information and current package insert, please visit www.Pfizer.com or call our medical communications department toll-free at 1-800-438-1985.

Please read this Patient Information carefully before using BeneFix and each time you get a refill. There may be new information. This brief summary does not take the place of talking with your doctor about your medical problems or your treatment.

What is BeneFix?

BeneFix is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Your doctor might also give you BeneFix before surgical procedures.

BeneFix is **NOT** used to treat hemophilia A.

What should I tell my doctor before using BeneFix?

Tell your doctor and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal medicines.

Tell your doctor about all of your medical conditions, including if you:

- have any allergies, including allergies to hamsters.
- are pregnant or planning to become pregnant. It is not known if BeneFix may harm your unborn baby.
- are breastfeeding. It is not known if BeneFix passes into the milk and if it can harm your baby.

How should I infuse BeneFix?

The initial administrations of BeneFix should be administered under proper medical supervision, where proper medical care for severe allergic reactions could be provided.

See the step-by-step instructions for infusing in the complete patient labeling.

You should always follow the specific instructions given by your doctor. If you are unsure of the procedures, please call your doctor or pharmacist before using.

Call your doctor right away if bleeding is not controlled after using BeneFix.

Your doctor will prescribe the dose that you should take. Your doctor may need to test your blood from time to time. BeneFix should not be administered by continuous infusion.

What if I take too much BeneFix?

Call your doctor if you take too much BeneFix.

What are the possible side effects of BeneFix?

Allergic reactions may occur with BeneFix. Call your doctor or get emergency treatment right away if you have any of the following symptoms:

wheezing	fast heartbeat
difficulty breathing	swelling of the face
chest tightness	faintness
turning blue (look at lips and gums)	rash
	hives

Your body can also make antibodies, called "inhibitors," against BeneFix, which may stop BeneFix from working properly.

Some common side effects of BeneFix are fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness and rash.

BeneFix may increase the risk of thromboembolism (abnormal blood clots) in your body if you have risk factors for developing blood clots, including an indwelling venous catheter through which BeneFix is given by continuous infusion. There have been reports of severe blood clotting events, including life-threatening blood clots in critically ill neonates, while receiving continuous-infusion BeneFix through a central venous catheter. The safety and efficacy of BeneFix administration by continuous infusion have not been established.

These are not all the possible side effects of BeneFix.

Tell your doctor about any side effect that bothers you or that does not go away.

How should I store BeneFix?

DO NOT FREEZE the BeneFix kit. The BeneFix kit can be stored at room temperature (below 86°F) or under refrigeration. Throw away any unused BeneFix and diluent after the expiration date indicated on the label.

Freezing should be avoided to prevent damage to the pre-filled diluent syringe.

BeneFix does not contain a preservative. After reconstituting BeneFix, you can store it at room temperature for up to 3 hours. If you have not used it in 3 hours, throw it away.

Do not use BeneFix if the reconstituted solution is not clear and colorless.

What else should I know about BeneFix?

Medicines are sometimes prescribed for purposes other than those listed here. Do not use BeneFix for a condition for which it was not prescribed. Do not share BeneFix with other people, even if they have the same symptoms that you have.

If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about BeneFix that was written for healthcare professionals.

This brief summary is based on BeneFix® [Coagulation Factor IX (Recombinant)] Prescribing Information LAB-0464-12.0, revised June 2020.

THANKS TO OUR VIRTUAL 5K SPONSORS!



SAY HELLO TO JAMES

He has hemophilia A and has gone through two major surgeries while keeping to his factor regimen with the support of his hemophilia care team

"RECOVERY WAS TOUGH,
BUT I LEARNED I HAD
MORE SUPPORT THAN
I THOUGHT POSSIBLE."



Read stories like James' in
Hello Factor magazine:
BleedingDisorders.com



TAKE CONTROL TO A HIGH LEVEL WITH REBINYN® IN HEMOPHILIA B

Rebiny® elevates factor levels above your normal levels^a

+94% Factor IX (FIX) levels achieved after an infusion^b

83-hr average half-life (3.5 day) in adults^a

With a single dose of Rebiny® 40 IU/kg in adults with $\leq 2\%$ FIX levels^a

Achieve higher factor levels for longer
Compared with Alprolix^{®c}, Rebiny® provides

4x

greater factor coverage

6x

higher factor levels at 7 days

Clayton, 34 years old, is a pilot and enjoys hiking and camping in his spare time. Clayton lives with hemophilia B.



Image of hemophilia patient shown is for illustrative purposes only.

^aIn a phase 3 study of adults, single dose pharmacokinetics were tested during the first Rebiny® 40 IU/kg dose in 6 adults.

^bBased upon a 2.34% increase in factor levels per IU/kg infused in adults.

^cBased upon a phase 1 study comparing a single 50 IU/kg dose of Rebiny® to a single 50 IU/kg dose of extended half-life rFIXc in 15 adults. To allow for direct comparison between products, all patients received the Alprolix standard 50 IU/kg dose.

INDICATIONS AND USAGE

What is Rebiny® Coagulation Factor IX (Recombinant), GlycoPEGylated?

Rebiny® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebiny® is used to treat and control bleeding in people with hemophilia B. Your healthcare provider may give you Rebiny® when you have surgery. Rebiny® is not used for routine prophylaxis or for immune tolerance therapy.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about Rebiny®?

- Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing Rebiny®.

Who should not use Rebiny®?

Do not use Rebiny® if you:

- are allergic to Factor IX or any of the other ingredients of Rebiny®.
- are allergic to hamster proteins.

What should I tell my health care provider before using Rebiny®?

Tell your health care provider if you:

- have or have had any medical conditions.
- take any medicines, including non-prescription medicines and dietary supplements.
- are nursing, pregnant, or plan to become pregnant.
- have been told you have inhibitors to Factor IX.

How should I use Rebiny®?

- Rebiny® is given as an infusion into the vein.
- Call your healthcare provider right away if your bleeding does not stop after taking Rebiny®.
- Do not stop using Rebiny® without consulting your healthcare provider.

What are the possible side effects of Rebiny®?

- Common side effects include swelling, pain, rash or redness at the location of the infusion, and itching.
- Call your healthcare provider right away or get emergency treatment right away if you get any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
- Tell your healthcare provider about any side effect that bothers you or that does not go away.
- Animals given repeat doses of Rebiny® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown.

Please see Brief Summary of Prescribing Information on the following page.

Rebiny® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Learn more at rebiny.com and connect with your local HCL



Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Rebiny® is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

© 2019 Novo Nordisk Printed in the U.S.A. US19REB00028 July 2019

rebiny®

Coagulation Factor IX (Recombinant), GlycoPEGylated

rebinyn®

Coagulation Factor IX (Recombinant), GlycoPEGylated

Brief Summary Information about: REBINYN® Coagulation Factor IX (Recombinant), GlycoPEGylated

Rx Only

This information is not comprehensive.

- Talk to your healthcare provider or pharmacist
- Visit www.novo-pi.com/REBINYN.pdf to obtain FDA-approved product labeling
- Call 1-844-REB-INYN

Read the Patient Product Information and the Instructions For Use that come with REBINYN® before you start taking this medicine and each time you get a refill. There may be new information.

This Patient Product Information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about REBINYN® after reading this information, ask your healthcare provider.

What is the most important information I need to know about REBINYN®?

Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center.

You must carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing REBINYN® so that your treatment will work best for you.

What is REBINYN®?

REBINYN® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Hemophilia B is an inherited bleeding disorder in all age groups that prevents blood from clotting normally.

REBINYN® is used to treat and control bleeding in people with hemophilia B.

Your healthcare provider may give you REBINYN® when you have surgery.

REBINYN® is not used for routine prophylaxis or for immune tolerance therapy.

Who should not use REBINYN®?

You should not use REBINYN® if you

- are allergic to Factor IX or any of the other ingredients of REBINYN®
- if you are allergic to hamster proteins

If you are not sure, talk to your healthcare provider before using this medicine.

Tell your healthcare provider if you are pregnant or nursing because REBINYN® might not be right for you.

What should I tell my healthcare provider before I use REBINYN®?

You should tell your healthcare provider if you

- Have or have had any medical conditions.
- Take any medicines, including non-prescription medicines and dietary supplements.
- Are nursing.
- Are pregnant or planning to become pregnant.
- Have been told that you have inhibitors to Factor IX.

How should I use REBINYN®?

Treatment with REBINYN® should be started by a healthcare provider who is experienced in the care of patients with hemophilia B.

REBINYN® is given as an infusion into the vein.

You may infuse REBINYN® at a hemophilia treatment center, at your healthcare provider's office or in your home. You should be trained on how to do infusions by your hemophilia treatment center or healthcare provider. Many people with hemophilia B learn to

infuse the medicine by themselves or with the help of a family member.

Your healthcare provider will tell you how much REBINYN® to use based on your weight, the severity of your hemophilia B, and where you are bleeding. Your dose will be calculated in international units, IU.

Call your healthcare provider right away if your bleeding does not stop after taking REBINYN®.

If your bleeding is not adequately controlled, it could be due to the development of Factor IX inhibitors. This should be checked by your healthcare provider. You might need a higher dose of REBINYN® or even a different product to control bleeding. Do not increase the total dose of REBINYN® to control your bleeding without consulting your healthcare provider.

Use in children

REBINYN® can be used in children. Your healthcare provider will decide the dose of REBINYN® you will receive.

If you forget to use REBINYN®

If you forget a dose, infuse the missed dose when you discover the mistake. Do not infuse a double dose to make up for a forgotten dose. Proceed with the next infusions as scheduled and continue as advised by your healthcare provider.

If you stop using REBINYN®

Do not stop using REBINYN® without consulting your healthcare provider.

If you have any further questions on the use of this product, ask your healthcare provider.

What if I take too much REBINYN®?

Always take REBINYN® exactly as your healthcare provider has told you. You should check with your healthcare provider if you are not sure. If you infuse more REBINYN® than recommended, tell your healthcare provider as soon as possible.

What are the possible side effects of REBINYN®?

Common Side Effects Include:

- swelling, pain, rash or redness at the location of infusion
- itching

Other Possible Side Effects:

You could have an allergic reaction to coagulation Factor IX products. **Call your healthcare provider right away or get emergency treatment right away if you get any of the following signs of an allergic reaction:** hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.

Your body can also make antibodies called "inhibitors" against REBINYN®, which may stop REBINYN® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.

You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness or swelling.

Animals given repeat doses of REBINYN® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown.

These are not all of the possible side effects from REBINYN®. Ask your healthcare provider for more information. You are encouraged to report side effects to FDA at 1-800-FDA-1088.

Tell your healthcare provider about any side effect that bothers you or that does not go away.

What are the REBINYN® dosage strengths?

REBINYN® comes in three different dosage strengths. The actual number of international units (IU) of Factor IX in the vial will be imprinted on the label and on the box. The three different strengths are as follows:

Cap Color Indicator	Nominal Strength
Red	500 IU per vial
Green	1000 IU per vial
Yellow	2000 IU per vial

Always check the actual dosage strength printed on the label to make sure you are using the strength prescribed by your healthcare provider.

How should I store REBINYN®?

Prior to Reconstitution (mixing the dry powder in the vial with the diluent):

Store in original package in order to protect from light. Do not freeze REBINYN®.

REBINYN® vials can be stored in the refrigerator (36-46°F [2°C-8°C]) for up to 24 months until the expiration date, or at room temperature (up to 86°F [30°C]) for a single period not more than 6 months.

If you choose to store REBINYN® at room temperature:

- Note the date that the product is removed from refrigeration on the box.
- The total time of storage at room temperature should not be more than 6 months. Do not return the product to the refrigerator.
- Do not use after 6 months from this date or the expiration date listed on the vial, whichever is earlier.

Do not use this medicine after the expiration date which is on the outer carton and the vial. The expiration date refers to the last day of that month.

After Reconstitution:

The reconstituted (the final product once the powder is mixed with the diluent) REBINYN® should appear clear without visible particles.

The reconstituted REBINYN® should be used immediately.

If you cannot use the reconstituted REBINYN® immediately, it should be used within 4 hours when stored at or below 86°F (30°C). Store the reconstituted product in the vial.

Keep this medicine out of the sight and out of reach of children.

What else should I know about REBINYN® and hemophilia B?

Medicines are sometimes prescribed for purposes other than those listed here. Do not use REBINYN® for a condition for which it is not prescribed. Do not share REBINYN® with other people, even if they have the same symptoms that you have.

More detailed information is available upon request.

Available by prescription only.

For more information about REBINYN®, please call Novo Nordisk at 1-844-REB-INYN.

Revised: 11/2017

REBINYN® is a trademark of Novo Nordisk A/S.

For Patent Information, refer to: <http://novonordisk-us.com/patients/products/product-patents.html>

Manufactured by:

Novo Nordisk A/S

Novo Allé, DK-2880 Bagsværd, Denmark

For information about REBINYN® contact:

Novo Nordisk Inc.

800 Scudders Mill Road

Plainsboro, NJ 08536, USA

© 2017 Novo Nordisk
USA17BI003951 12/2017





RESOURCES FOR MENTAL HEALTH INFORMATION

National Institute of Mental Health www.nimh.gov 899-415-8051

National Center for Post Traumatic Stress Network www.ptsd.va.gov 802-296-6300

National Institute of Alcohol Abuse www.niaa.nih.gov 301-443-3860

National Institute of Drug Abuse www.drugabuse.gov 301-443-1124

Jason Foundation www.jasonfoundation.com 615-264-2323 Prevents teen suicide

American Foundation for Suicide Prevention www.afsp.org 2121-363-3500

• • • • •

MENTAL HEALTH HOTLINES

National Suicide Prevention Lifeline www.suicidepreventionlifeline.org 800-273-TALK

Veterans Crisis Line www.veteranscrisisline.net 800-273-TALK (8255) Press 1 text a message to 838255

JED Foundation (Teens, Young Adults) www.jedfoundation.org 800-233-TALK Text START to 741741

National Domestic Violence Hotline www.thehotline.org 800-799-SAFE

National Child Abuse Hotline www.childhelp.org 800-422-4453

Trevor Lifeline (LGBTQ) www.thetrevorproject.org 866-488-7386 Text START to 678678

Substance Abuse and Mental Health Services Administration
www.samhsa.gov/find-help/national-helpline 800-662-4357

• • • • •

COVID-19 RESOURCES

A Project of Shine www.virusanxiety.com

COVID-19 Mental Health Resource Hub PsychHub www.psychhub.com

COVID-19 Information National Hemophilia Foundation www.hemophilia.org

COVID-19 Resources Hemophilia Federation of America www.hemophiliafed.org

• • • • •

MENTAL HEALTH CARE

Psychology Today www.psychology.com This website provides the opportunity to browse mental health professionals by location, specialties and form of payment accepted.

Depression and Bipolar Support Alliance www.dbsalliance.org DBSA offers support groups for individuals living with depression and bipolar disorder.

National Alliance on Mental Illness www.nami.org NAMI provides support groups for the individual living with a mental illness and his/her family, advocates for mental health issues and works to reduce stigma associated with psychological conditions.

Better Help www.betterhelp.com

Talk Space www.talkspace.com

Give An Hour www.giveanhour.org Website listing of mental health professionals who have agreed to provide short term psychological counseling to veterans and their families free of charge.

Grief Share www.griefshare.org Grief Share facilitates support groups throughout the country for individuals experiencing loss and grief.

Coping Strategies <https://emetgency.cdc.gov/coping/selfcare.asp>
<https://www.cdc.gov/childrenindisasters/helping-children-cope.html>

HTC CORNER



In collaboration with Dayton Children's HTC, SWOHF has recently switched to a new provider for our Medical ID's. We are happy to announce our partnership with American Medical ID. They offer a great variety of quality products at a discount to Chapters. Additionally, their Customer Service is exceptional, their shipping is fast and their prices are significantly less than MedicAlert (our previous supplier).

Free products are included with every order: An emergency medical ID card, a small ID charm and an exclusive engraved rectangular "InCase" phone ID that easily attaches to your cellphone case or any flat object, such as a suitcase, briefcase or laptop.

SWOHF is grateful for grant funding and donations that facilitate these purchases on behalf of our Greater Dayton Bleeding Disorders Community. So when you go to the HTC for your next visit, you can view sample products available and complete a form to request a new bracelet or necklace according to Chapter guidelines.



[Phone not included]



JOY@SWOHF.ORG



3131 SOUTH DIXIE DRIVE, SUITE 103
MORaine, OH 45439



937-298-8000



CONTACT US



WE WANT TO HEAR FROM YOU!

MISSION STATEMENT

SWOHF helps improve the quality of life for those affected by hemophilia, von Willebrand disease, and other bleeding disorders by providing support education, networking, advocacy, and services to individuals, their families and the community.

EXECUTIVE DIRECTOR

Joy Linder

DISCLAIMER

The material provided in Factor Notes is for your general information only. SWOHF does not give medical advice or engage in the practice of medicine. SWOHF under no circumstances recommends particular treatment for specific individuals, and in all cases recommends that you consult your physician or treatment center before pursuing any course of treatment.

Southwestern Ohio Hemophilia Foundation

3131 South Dixie Drive, Suite 103

Moraine, OH 45439



SWOHF
SOUTHWESTERN OHIO
HEMOPHILIA FOUNDATION